Fused azepinone cyclin dependent kinase inhibitors

A composition comprising an amount of a compound effective to reduce cell proliferation according to the formula

• wherein A is a hydroxy, alkoxy, sulfhydryl, or sulfide moiety bonded to ring B by a single bond or is a carbonyl or thiocarbonyl moiety bonded to ring B by a double bond;
• R2 is selected from the group consisting of hydrogen, aryl, alkoxycarbonylalkyl, alkanoyl, alkoxycarbonyl, alkyl, alkenyl and alkynyl groups;
• R4-R7 are independently selected from the group consisting of alkoxy, amino, alkanoyl, alkenoyl, alkynoyl, alkyl, alkenyl, alkynyl, cyano, nitro, carboxyl, halogen, hydrogen, hydroxyl, and imino groups;
• R8-R11 are independently selected from the group consisting of alkyl alkoxy, alkenyl alkoxy, alkynyl alkoxy, alkanoyl, alkenoyl, alkynoyl, cyano, nitro, halogen, hydrogen and hydroxyl groups;
• R12 is selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, carboxy and hydrogen;
• and
• where ring A or D includes a substituent other than hydrogen and halogen.

A method for treating a subject, comprising:

• providing a compound effective against a disorder selected from the group consisting of leukemia, lung cancer, central nervous system cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, and breast cancer, the compound having the formula
• wherein A is a hydroxy, alkoxy, sulfhydryl, or sulfide moiety bonded to ring B by a single bond or is a carbonyl or thiocarbonyl moiety bonded to ring B by a double bond;
• R2 is selected from the group consisting of hydrogen, aryl, alkoxycarbonylalkyl, alkanoyl, alkoxycarbonyl, alkyl, alkenyl and alkynyl groups;
• R4-R7 are independently selected from the group consisting of alkoxy, amino, alkanoyl, alkenoyl, alkynoyl, alkyl, alkenyl, alkynyl, cyano, nitro, carboxyl, halogen, hydrogen, hydroxyl, and imino groups;
• R8-R11 are independently selected from the group consisting of alkyl alkoxy, alkenyl alkoxy, alkynyl alkoxy, alkanoyl, alkenoyl, alkynoyl, cyano, nitro, halogen, hydrogen and hydroxyl groups;
• R12 is selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, carboxy and hydrogen;
• and
• administering the compound to the subject.

A compound selected from the group consisting of 2,9-dibromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one;

• 8,10-dichloro-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one;
• 2-iodo-9-bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one;
• 2-iodo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one;
• 6-methylthio-7,12-dihydro-indolo[3,2-d][1]benzazepine;
• 9-bromo-7,12-dihydro-5-methyloxycarbonylmethyl-indolo[3,2-d][1]benzazepin-6(5H)-one;
• 9-bromo-7,12-dihydro-5-methyl-indolo[3,2-d][1]benzazepin-6(5H)-one;
• 9-bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-thione;
• 9-bromo-5,12-bis-(t-butyloxycarbonyl)-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one;
• 9-bromo-12-(t-butyloxycarbonyl)-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one;
• 9-bromo-5,7-bis-(t -but yloxycarbonyl)-7,12-dihydro-indolo[3,2-cl][1]benzazepin-6(5H)-one;
• 9-bromo-5,7,12-tri-(t-butyloxycarbonyl)-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one;
• 9-bromo-7,12-dihydro-12-methyloxycarbonylmethyl-indolo[3,2-d][1]bcnzazepin-6(5H)-one;
• 9-bromo-7,12-dihydro-12-(2-hydroxyethyl)-indolo[3,2-d][1]benzazepin-6(5H)-one;
• 2,9-dibromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one;
• 8,10-dichloro-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one;
• 5-benzyl-9-bromo-7,12-dihydro-5-methyl-indolo[3,2-d][1]benzazepin-6(5H)-one;
• 9-bromo-7,12-dihydro-12-methyl-indolo[3,2-d][1]benzazepin-6(5H)-one;
• 9-bromo-12-ethyl-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one;
• 11-bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one;
• 2-iodo-9-bromo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one;
• 2-iodo-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one;
• and 9-fluoro-7,12-dihydro-indolo[3,2-d][1]benzazepin-6(5H)-one.